TQ B3525
Alternative Names: TQ-B3525Latest Information Update: 15 Jul 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Developer Chia Tai Tianqing Pharmaceutical Group; Peking University People's Hospital
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Follicular lymphoma
- Phase II Cervical cancer; Endometrial cancer; Mantle-cell lymphoma; Ovarian cancer
- Phase I/II Chronic lymphocytic leukaemia; Non-small cell lung cancer; Osteosarcoma
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Follicular lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 Dec 2023 Preregistration for Follicular lymphoma (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (PO) (SEC file 2023- HUTCHMED)
- 31 Dec 2023 National Medical Products Administration (NMPA) accepts NDA for TQ-B3525 for follicular lymphoma for review (SEC file 2023- HUTCHMED)